Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

AMYLYX PHARMACEUTICALS, INC.

(AMLX)
  Report
Real-time Estimate Cboe BZX  -  01:49 2022-11-28 pm EST
37.00 USD   -4.52%
11/22Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference
BU
11/10Amylyx Pharmaceuticals Reports Narrowed Q3 Net Loss, Small Increase in Revenue
MT
11/10Transcript : Amylyx Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Amylyx Shares Rally Premarket on FDA Approval of ALS Drug

09/30/2022 | 04:15am EST

By Colin Kellaher


Shares of Amylyx Pharmaceuticals Inc. rose sharply in premarket trading Friday after the U.S. Food and Drug Administration approved Relyvrio, the company's new drug for amyotrophic lateral sclerosis, or ALS.

The drug is the first in five years to win an FDA green light for ALS, a progressive neurodegenerative disease also known as Lou Gehrig's disease.

Analyst Neena Bitritto-Garg at Citi said she expects demand for Relyvrio will be very strong at launch, with potential for meaningful out-performance versus Wall Street's expectations.

She termed the label for the label for Relyvrio as broad and clean, noting that it makes the drug the only approved ALS therapy with both a function and survival benefit on the label.

Cambridge, Mass., biopharmaceutical company Amylyx said doctors can begin prescribing Relyvrio immediately, adding that it expects specialty pharmacies will be able to start filling prescriptions and shipping the drug in the next four to six weeks.

Amylyx shares, which closed Thursday at $30.19, were recently up 7.7% to $32.51 in premarket trading.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

09-30-22 0615ET

All news about AMYLYX PHARMACEUTICALS, INC.
11/22Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Confere..
BU
11/10Amylyx Pharmaceuticals Reports Narrowed Q3 Net Loss, Small Increase in Revenue
MT
11/10Transcript : Amylyx Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 10, 202..
CI
11/10AMYLYX PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditi..
AQ
11/10Earnings Flash (AMLX) AMYLYX PHARMACEUTICALS Posts Q3 Revenue $345,000
MT
11/10Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results
BU
11/10Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
CI
11/03Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2..
BU
11/02Amylyx Pharmaceuticals, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
11/02Amylyx Pharmaceuticals, Inc. Announces Resignation of Isaac Cheng as Board of Directors
CI
More news
Analyst Recommendations on AMYLYX PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 2,78 M - -
Net income 2022 -206 M - -
Net cash 2022 132 M - -
P/E ratio 2022 -11,0x
Yield 2022 -
Capitalization 2 567 M 2 567 M -
EV / Sales 2022 876x
EV / Sales 2023 17,9x
Nbr of Employees 237
Free-Float 75,4%
Chart AMYLYX PHARMACEUTICALS, INC.
Duration : Period :
Amylyx Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMYLYX PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 38,75 $
Average target price 48,75 $
Spread / Average Target 25,8%
EPS Revisions
Managers and Directors
Joshua B. Cohen Co-Chief Executive Officer & Executive Director
Justin Klee Co-Chief Executive Officer & Executive Director
James M. Frates Chief Financial Officer
George M. Milne Chairman
Patrick D. Yeramian Chief Medical Officer & Global Head-Clinical R&D
Sector and Competitors